Details

Autor(en) / Beteiligte

• Hodi, F. Stephen
• O'Day, Steven J
• McDermott, David F
• Weber, Robert W
• Weber, Jeffrey S
• Sosman, Jeffrey A
• Haanen, John B
• Gonzalez, Rene
• Robert, Caroline
• Schadendorf, Dirk
• Hassel, Jessica C
• Akerley, Wallace
• van den Eertwegh, Alfons J.M
• Lutzky, Jose
• Lorigan, Paul
• Vaubel, Julia M
• Linette, Gerald P
• Hogg, David
• Ottensmeier, Christian H
• Lebbé, Celeste
• Peschel, Christian
• Quirt, Ian
• Clark, Joseph I
• Wolchok, Jedd D
• Tian, Jason
• Yellin, Michael J
• Nichol, Geoffrey M
• Hoos, Axel
• Urba, Walter J

Titel

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ist Teil von

• The New England journal of medicine, 2010-08, Vol.363 (8), p.711-723

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The authors treated 676 patients with metastatic melanoma with an antibody to CTLA-4 (ipilimumab), the antibody plus a gp100 vaccine, or the vaccine alone. Patients who received ipilimumab with or without gp100 vaccine survived nearly 4 months longer than did those who received the gp100 vaccine alone. Adverse immune-related events were noted and some were severe, but most were reversible with appropriate treatment. The incidence of metastatic melanoma has increased over the past three decades, 1 , 2 and the death rate continues to rise faster than the rate with most cancers. 3 The World Health Organization (WHO) estimates that worldwide there are 66,000 deaths annually from skin cancer, with approximately 80% due to melanoma. 4 In the United States alone, an estimated 8600 persons died from melanoma in 2009. 1 The median survival of patients with melanoma who have distant metastases (American Joint Committee on Cancer stage IV) is less than 1 year. 5 , 6 No therapy is approved beyond the first-line therapy for metastatic melanoma, and enrollment . . .